CClinicalTrials.gg
CompletedNCT03973801Updated Mar 10, 2020

Feasibility of Auricular Acupressure as an Adjunct Treatment for Neonatal Abstinence Syndrome (NAS)

An interventional study of Auricular acupuncture in Neonatal Abstinence Syndrome and Withdrawal, sponsored by Vanderbilt University Medical Center. Completed at 1 site in United States. Open to participants aged Up to 24 Hours. Per ClinicalTrials.gov, last updated 2020-03-10.

Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
Up to 24 Hours
Sex
All
01

Study summary

This study will assess the feasibility of implementing auricular acupressure as an additional non-pharmacologic therapy for neonates at risk for developing neonatal abstinence syndrome (NAS) at Monroe Carrell Jr Children's Hospital at Vanderbilt University Medical Center (VUMC).

Read the detailed description

NAS is a condition in which newborns experience withdrawal symptoms as a result of in utero exposure to opioids and/or other substances ingested by the mother. The condition has significantly risen over the past 20 years. First line treatments for NAS involve the maximization of non-pharmacologic therapies. NAS management focuses on reducing or eliminating the need for medication management to prevent further developmental complications, promote maternal bonding, and reduce hospital length of stay.

Auricular acupuncture has been used for the treatment of addiction and has demonstrated efficacy in the adult population. Current evidence suggests that acupuncture is safe and beneficial for multiple conditions that impact neonatal and pediatric populations including NAS. Acupressure is a less invasive therapy and may serve as an additional non-pharmacological adjunct to ease the severe discomfort of withdrawal in neonates at risk for NAS.

This study will assess the feasibility of implementing auricular acupressure as an additional non-pharmacologic therapy for neonates at risk for developing neonatal abstinence syndrome (NAS) at Monroe Carrell Jr Children's Hospital at Vanderbilt University Medical Center (VUMC).

02

Conditions studied

  • Neonatal Abstinence Syndrome
  • Withdrawal

Keywords

  • Acupressure
03

In context

Neonatal Abstinence Syndrome

65 studies on the registry are indexed under Neonatal Abstinence Syndrome; 6 are open to participants now.

This study's enrollment of 12 is below the median of 44 across 50 interventional studies indexed under Neonatal Abstinence Syndrome.

Browse Neonatal Abstinence Syndrome studies →

Lead sponsor

Vanderbilt University Medical Center is the lead sponsor of 824 studies on the registry; 164 are open to participants now.

Of its 122 completed or terminated interventional studies of FDA-regulated products, 91 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 24 Hours
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 37 weeks gestational age or greater
  • Maternal age 16 or older
  • Substance exposure in utero including opioids, illicit drugs, or other medications that cause neonatal withdrawal

Exclusion criteria

Exclusion Criteria:

  • Birth trauma
  • Neonatal asphyxia
  • Maternal or neonatal infection
  • Congenital abnormalities
  • Requiring Neonatal Intensive Care Unit (NICU) care
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Auricular acupressure

    Other: Auricular acupuncture

Interventions

  • OtherAuricular acupuncture

    National Acupuncture Detoxification Association (NADA) protocol for auricular acupressure will be initiated within 24 hours of delivery and continued until withdrawal symptoms measure 6 or less for 12 hours on the modified Finnegan score and/or the morning of expected discharge as in line with standard of care.

06

What researchers measure

Primary outcomes

  1. Percent of eligible patients enrolled

    Time frame: end of study enrollment (about 12 weeks)

  2. Percent of patients prematurely terminating treatment

    Time frame: hospital discharge (about 48-72 hours after delivery)

  3. Percent of participants completing all study assessments

    Time frame: hospital discharge (about 48-72 hours after delivery)

  4. Percent of data collection procedures completed

    Time frame: hospital discharge (about 48-72 hours after delivery)

  5. Percent of missing medical record data

    Time frame: hospital discharge (about 48-72 hours after delivery)

Secondary outcomes

  1. Percent of providers enrolled in 3 day training course for NADA protocol

    Time frame: Prior to start of study enrollment (May 31, 2019)

  2. Percent of providers completing 3 day training course for NADA protocol

    Percent of providers completing 3 day training course for NADA protocol: The training course includes a national, standardized curriculum, clinical demonstration and skills lab. Providers are trained in application of acupuncture needles which are placed at the same location as acupressure stickers.

    Time frame: Day 3 of training

  3. Percent of providers completing clinical competency with NADA protocol

    Percent of providers completing clinical competency with NADA protocol: Following the training course providers must submit pictures to the NADA instructor with a clinical log of 40 appropriately placed acupuncture needles in accordance with the NADA protocol. Training includes

    Time frame: Prior to start of study enrollment (May 31, 2019)

  4. Percent of providers receiving NADA certification

    Percent of providers receiving NADA certification: Once clinical practice is complete and verified by a NADA trainer, providers will receive a NADA certification

    Time frame: Prior to start of study enrollment (May 31, 2019)

  5. Percent of providers receiving credentialing

    Following certification of the providers, competency of acupressure placement on neonates for the specific study protocol will be demonstrated via simulation lab. Providers must perform the acupressure, in accordance with the NADA protocol, on a neonatal manikin, and documentation of the appropriate technique will be completed for credentialing purposes. Providers will submit the NADA certificate, a skills checklist that documents appropriate NADA technique on a neonate manikin, and a neonatal simulation lab certificate for credentialing to perform NADA protocol at VUMC.

    Time frame: Prior to start of study enrollment (May 31, 2019)

  6. Client Satisfaction Questionnaire (CSQ*) Score

    On day of discharge, the parent(s) will receive the Client Satisfaction Questionnaire (CSQ8) to assess parental satisfaction of acupuncture as an additional therapy. The CSQ8 is an 8 item measure of client satisfaction with services. Items are questions inquiring about respondents' opinions and conclusions about services they have received. Response options differ from item to item, but all are based on a four-point scale. The overall score is produced by summing all item responses. CSQ-8 version scores range from 8 to 32, with higher values indicating higher satisfaction.

    Time frame: Day of discharge (about 48-72 hours after delivery)

  7. Intervention Appropriateness Measure (IAM) Score

    Provider and staff acceptability of acupressure as an additional non-pharmacologic treatment will be measured with the Intervention Appropriateness Measure (IAM). The IAM is a four-item measure of the appropriateness of an intervention. Each item of the score is rated on a five point scale where 1 equals completely disagree and 5 equals completely agree. The total score ranges from 5 to 20, with a higher score indicating a higher level of appropriateness.

    Time frame: Day of hospital discharge of baby (about 48-72 hours after delivery)

  8. Acceptability of Intervention Measure (AIM)

    Provider and staff acceptability of acupressure as an additional non-pharmacologic treatment will be measured with the Acceptability of Intervention Measure (AIM). The AIM is a four-item measure of the acceptability of an intervention. Each item of the score is rated on a five point scale where 1 equals completely disagree and 5 equals completely agree. The total score ranges from 5 to 20, with a higher score indicating a higher level of acceptability.

    Time frame: Day of hospital discharge of baby (about 48-72 hours after delivery)

  9. Feasibility of Intervention Measure (FIM)

    Provider and staff acceptability of acupressure as an additional non-pharmacologic treatment will be measured with the Feasibility of Intervention Measure (FIM). The FIM is a four-item measure of the feasibility of an intervention. Each item of the score is rated on a five point scale where 1 equals completely disagree and 5 equals completely agree. The total score ranges from 5 to 20, with a higher score indicating a higher level of feasibility.

    Time frame: Day of hospital discharge of baby (about 48-72 hours after delivery)

07

Study locations

1 site
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03973801
Lead sponsor
Vanderbilt University Medical Center
Collaborators
Medical University of South Carolina
Responsible party
Heather Jackson (Associate in Anesthesiology, Division of Pain Medicine, Vanderbilt University Medical Center) — Principal investigator
First posted
Jun 4, 2019
Start date
Aug 19, 2019
Primary completion
Sep 16, 2019
Completion
Sep 16, 2019
Last update
Mar 10, 2020

Study contacts

Heather Jackson, MSN
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion